Cancer remains a leading cause of death, due in great part to delayed diagnosis. Cancer detection is, however, difficult in patients without organ-specific symptoms. This interdisciplinary long-term project investigates blood biomarkers indicative of occult cancer, with a focus on proteomics, metabolomics and glycomics (liquid biopsies).
Conducting two large clinical studies (including patients at risk of occult cancer), the researchers are developing a simple blood test selecting high-risk patients for a rapid and targeted cancer diagnostic work-up. This could result in shortened diagnostic delay, prompt cancer treatment, and ultimately reduce cancer-related morbidity and mortality.
